Abstract:

【Abstract】Objective To assess the clinical efficacy and safety of calcipotriol betamethasone ointment (Daivobet?) in Chinese patients with psoriasis vulgaris. Methods 90 patients were randomly divided into three groups to receive calcipotriol betamethasone ointment, calcipotriol ointment or mometasone furoate ointment once daily for 4 weeks. The safety and efficacy of the three groups were evaluated on week1, 2 and 4 after the first dosage. Results After 4 weeks of treatment, effective rate of calcipotriol betamethasone-treated patients was much higher than calcipotriol-treated patients and mometasone furoate-treated patients (73.33% vs 50% vs 46.67%;P＜0.01), psoriasis area and severity index(PASI) of calcipotriol betamethasone-treated patients was much lower than the other two groups (P＜0.05), and calcipotriol betamethasone-treated patients experienced a greater decrease in PASI compared with the other two groups (0.77±0.16 vs 0.57±0.15 vs 0.54±0.16;P＜0.01). One calcipotriol betamethasone-treated patient and one calcipotriol-treated patient received increased serum calcium without syndromes after 4 weeks treatment, which decreased to normal value after drug withdrawal for 1 week. Five calcipotriol betamethasone-treated patients and five calcipotriol-treated patients receiced tolerated local stimulation on test positions during therapy. Conclusions Daily calcioptriol betamethasone ointment is an effective, safe, convenient , well-tolerated treatment with a rapid onset of action for stable psoriasis vulgaris in Chinese patients.

Key words: Clinical observation